Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat extension study in pyruvate kinase deficiency
NCT03853798Phase 3Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (3 cohorts), sponsored by Agios Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events at 197 weeks, Treatment Emergent Adverse Events Leading to Dose Reduction, Treatment Interruption and Treatment Discontinuation at 197 weeks and 8 more. Started Mar 2019; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT03853798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853798.